Brought to you by 
Navire Pharma launched with $30mm Series A from parent BridgeBio
18 Dec 2020
Executive Summary
Navire Pharma (small-molecule cancer therapies) has launched with a $30mm Series A investment from parent BridgeBio Pharma, plus IP and a drug development team from MD Anderson Cancer Center.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com